A Novel Approach to Platinum-Resistant Ovarian Cancer: Results from the Elenagen Phase II Study (ESGO 2026)
April 13, 2026
Beyond Checkpoint Inhibitors: Reimagining the Future of Cancer Immunotherapy
June 23, 2026New Developments in Ovarian Cancer Treatments
Dr. Alex Shneider, CEO of Curelab Oncology and the developer of Elenagen joins eHealth Radio and the Health News and Cancer Information Channels to discuss this breakthrough.
Listen to host Eric Dye & guest Dr. Alex Shneider discuss the following:
- For listeners who may not be familiar with platinum-resistant ovarian cancer, can you explain why this form of the disease is so difficult to treat and where the biggest unmet medical needs are today?
- Your recent clinical findings suggest that adding Elenagen to gemcitabine may significantly extend survival. What stood out most to you in the trial results, and why do you believe this combination showed promise?
- Elenagen is described as a DNA-based therapy targeting p62/SQSTM1. How does this approach differ from traditional chemotherapy or existing immunotherapy treatments for ovarian cancer?
4. The study was conducted in women whose cancers had already stopped responding to platinum-based therapies. What kinds of patients could potentially benefit most from Elenagen if future trials continue to show positive results?
Dr. Alex Shneider has over 25 years of biotech and entrepreneurial experience. Currently She is Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and Cell Cycle. The past achievements and activities include but are not limited to drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
Dr. Alex Shneider, CEO of Curelab Oncology and the developer of Elenagen joins eHealth Radio and the Health News and Cancer Information Channels to discuss this breakthrough.
